Loading…
Loading…
Neuronata-R retains conditional approval in South Korea PR Newswire SEOUL, South Korea, July 19, 2026
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Series J First Preferred Share quarterly dividend in release dated July 13, 2026, should read: $0.39660 (instead of $0.265625). The updated release reads EMERA DECLARES QUARTERLY DIVIDENDS On July 13, 2026, the Board of Directors of Emera Inc. (TSX/NYSE: EMA) declared quarterly dividends on its common shares and First Preferred Shares, each of which is payable on and after August 17, 2026 to the applicable shareholders of record at the close of business on.
[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy ag
HALIFAX, Nova Scotia--(BUSINESS WIRE)--On July 13, 2026, the Board of Directors of Emera Inc. (TSX/NYSE: EMA) declared quarterly dividends on its common shares and First Preferred Shares, each of which is payable on and after August 17, 2026 to the applicable shareholders of record at the close of business on August 3, 2026, as follows: $0.7325 per common share; $0.3094 per Series A First Preferred Share; $0.40213 per Series C First Preferred Share; $0.28125 per Series E First Preferred Share;.
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Today Emera (TSX/NYSE: EMA) announced that it will release its Q2 2026 results on Friday, August 7, 2026, before markets open. The Company will host a teleconference and webcast the same day at 9:30 a.m. Atlantic (8:30 a.m. Eastern) to discuss the results. Analysts and other interested parties in North America are invited to participate by dialing 1-800-717-1738. International parties are invited to participate by dialing 1-289-514-5100. Participants shoul.
Johnson and Johnson presents new IMAAVYÂ (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained dise
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positi
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) acro
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for EMA and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.